A Phase II, Multicentre, Double-blind, Placebo Controlled, Pilot Study to Evaluate the Safety and Efficacy of CUV1647 Administered as A Subcutaneous Bioresorbable 16mg Implant in Patients Undergoing Photodynamic Therapy (PDT) utilising Porfimer Sodium To determine whether CUV1647 implants can reduce the period of phototoxicity experienced by patients who have undergone photodynamic therapy with porfimer sodium.

• Country None
• organs None
• Specialty None

A Phase III, randomised, double blind, placebo controlled, parallel group study, to evaluate the safety and efficacy of subcutaneous implants of afamelanotide (16 mg) in patients suffering from polymorphic light eruption (PLE) Primary objectives - To determine if afamelanotide can reduce the severity of PLE related pruritis.

• Country None
• organs None
• Specialty None

A Phase III, randomised, double blind, placebo controlled study to evaluate the safety and efficacy of subcutaneous implants of CUV1647 in patients suffering from polymorphic light eruption (PLE) •Evaluate whether CUV1647 prevents episodes or reduces the severity of symptoms in patients with PLE •Evaluate the safety and tolerability of CUV1647 •Evaluate the effect of CUV1647 on the use of resc...

• Country None
• organs None
• Specialty None

A Phase III, randomised, double blind, placebo controlled study to evaluate the safety and efficacy of subcutaneous implants of afamelanotide (16 mg) in patients suffering from polymorphic light eruption (PLE) Primary objective To determine whether afamelanotide can reduce the severity of outbreaks of PLE.

• Country None
• organs None
• Specialty None

CLINUVEL CUV011 : Essai de phase 2 randomisé, en double aveugle, évaluant l’efficacité et la tolérance d’un implant sous cutané d’afamelanotide dans la prévention du cancer de la peau, chez des patients greffés ayant un risque élevé de cancer. [Informations issues du site clinicaltrials.gov et traduites par l'INCa] [essai clos aux inclusions] A multicenter, randomised, double-blind, placebo controlled, phase II study to evaluate the safety and efficacy of subcutaneous bioresorbable implants of afamelanotide (CUV1647) for the prophylactic t...

• Country France
• organs Peau - autres
• Specialty Autres (cryothérapie, radiofréquence, homéopathie,...)

A Phase II, Open Label Pilot Study to Evaluate the Safety and Efficacy of A Bioresorbable Subcutaneous Implant of CUV1647 in Patients with Solar Urticaria (SU) To determine whether a CUV1647 implant can reduce the susceptibility of patients with Solar Urticaria to provocation with a standardized light source (measured as a change in minimum urticarial dose, ...

• Country None
• organs None
• Specialty None

A Multicentre, Randomised, Double-Blind, Placebo-Controlled Phase II Study to Evaluate the Safety and Efficacy of Subcutaneous Bioresorbable Implants of CUV1647 for the Prophylactic Treatment of Pre-Cancerous Skin Lesions of the Head, Forearms and Hands in Immune Compromised, Organ Transplant Patients - To determine the effect of CUV1647 administered from slow release subcutaneous implants on the number of actinic keratoses (AKs) on the head, forearms and back of hands during a 24 month test period...

• Country None
• organs None
• Specialty None

A Phase II, Randomised, Open Label Pilot Study to Evaluate the Efficacy and Safety of Two Dosage Regimens of Subcutaneous Bioresorbable Afamelanotide Implants in Patients with Mild to Moderate Acne Vulgaris Primary objective: - To determine the effect of afamelanotide on the facial inflammatory acne-related lesions in patients with mild to moderate acne vulgaris.

• Country None
• organs None
• Specialty None

A Phase III, multicentre, double–blind, placebo controlled, cross over study to evaluate the safety and efficacy of subcutaneous bioresorbable implants of afamelanotide in the treatment of solar urticaria (SU) Primary objective: To determine if afamelanotide increases the minimal urticarial dose (MUD) in subjects with solar urticaria (SU).

• Country None
• organs None
• Specialty None

A Phase III, Multicentre, Double-Blind, Randomised, Placebo-Controlled Study to Confirm the Safety and Efficacy of Subcutaneous Bioresorbable Afamelanotide Implants in Patients with Erythropoietic Protoporphyria (EPP) Primary objective: - To determine whether afamelanotide can reduce the severity of phototoxic reactions in patients with EPP.

• Country None
• organs None
• Specialty None